Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name JAK1 A634D
Gene Variant Detail

JAK1 A634D (gain of function)

Relevant Treatment Approaches JAK Inhibitor (Pan) JAK Inhibitor (Pan) - ATP competitive JAK1 Inhibitor JAK1 Inhibitor - ATP competitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
JAK1 A634D hematologic cancer sensitive JAK1 Inhibitor - ATP competitive Ruxolitinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing JAK1 A634D were sensitive to treatment with Jakafi (ruxolitinib) in culture, demonstrating decreased cell proliferation (PMID: 31976485). 31976485
JAK1 A634D hematologic cancer sensitive JAK Inhibitor (Pan) - ATP competitive Tofacitinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing JAK1 A634D were sensitive to treatment with Xeljanz (tofacitinib) in culture, demonstrating decreased cell proliferation (PMID: 31976485). 31976485
JAK1 A634D hematologic cancer sensitive JAK1 Inhibitor - ATP competitive Baricitinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing JAK1 A634D were sensitive to treatment with Baricitinib (LY3009104) in culture, demonstrating decreased cell proliferation (PMID: 31976485). 31976485
JAK1 A634D hematologic cancer sensitive Decernotinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing JAK1 A634D were sensitive to treatment with Decernotinib (VX-509) in culture, demonstrating decreased cell proliferation (PMID: 31976485). 31976485
JAK1 A634D hematologic cancer sensitive JAK Inhibitor (Pan) ASP015K Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing JAK1 A634D were sensitive to treatment with ASP015K (peficitinib) in culture, demonstrating decreased cell proliferation (PMID: 31976485). 31976485
JAK1 A634D hematologic cancer sensitive JAK1 Inhibitor Upadacitinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing JAK1 A634D were sensitive to treatment with Rinvoq (upadacitinib) in culture, demonstrating decreased cell proliferation (PMID: 31976485). 31976485
JAK1 A634D hematologic cancer sensitive JAK Inhibitor (Pan) - ATP competitive Tofacitinib Preclinical - Cell culture Actionable In a preclinical study, Xeljanz (tofacitinib) treatment resulted in decreased viability of transformed cells expressing JAK1 A634D in culture (PMID: 34496019). 34496019
JAK1 A634D hematologic cancer sensitive JAK1 Inhibitor - ATP competitive Ruxolitinib Preclinical - Cell culture Actionable In a preclinical study, Jakafi (ruxolitinib) treatment inhibited Stat5 signaling and decreased viability of transformed cells expressing JAK1 A634D in culture (PMID: 34496019). 34496019